Dimiracetam
Experimental racetam-related compound for nerve (neuropathic) pain; worked in animal studies, not proven in humans.
Pharmacology
Contents
DETAILED OVERVIEW
What is Dimiracetam?
Dimiracetam is an experimental compound related to the racetams. It was originally developed to improve thinking, but was later studied mainly in long-lasting pain linked to nerve injury, chemotherapy or joint wear. It is not an approved medicine; in Australia it is classed as prescription-only.
In the spinal cord it reduces the excessive release of glutamate, a messenger substance that excites nerve cells, which dampens pain signaling. In animal studies it durably reduced pain hypersensitivity, and the effect persisted after the compound had left the body. So far it has been studied mainly in animals and is not proven in humans: although it reached early clinical trials, the results are not available. There is no detailed human side-effect data, so effects such as dizziness or headache cannot be ruled out. There is no safety data for pregnancy and breastfeeding.
Mechanism
Reduces NMDA-linked glutamate release
Evidence
Mostly preclinical (animal models)
Legal status
Investigational; AU: prescription-only
No anecdote collected yet.
Receptor profile
- NMDA receptors (GluN1 / GluN2A)Moderate
- Glutamatergic signalingModerate
- Neuropathic pain pathwaysModerate
- Learning / memory circuitsWeak
Safety
Side effects, stop signs, contraindications
Side effects · 4
- Described as well tolerated in animal studies; human safety is not fully established
- A detailed human side-effect profile is not published in the public literature
- As an NMDA-glutamatergic modulator, dose-dependent central nervous system effects (e.g. dizziness, headache) cannot be theoretically excluded
- No long-term human safety data are available
Contraindications · 4
- Pregnancy and breastfeeding: no safety data, should be avoided
- Hepatic or renal impairment: no human pharmacokinetic data, caution / medical supervision
- Investigational compound: not approved for self-medication outside a clinical trial
- Prescription-only in Australia (Schedule 4): a legal restriction applies
Related Nootropics
Same therapeutic category
Studies
Related research and clinical findings
Broad spectrum and prolonged efficacy of dimiracetam in models of neuropathic pain
Fariello RG, Ghelardini C, Di Cesare Mannelli L, Bonanno G, Pittaluga A, Milanese M, Misiano P, Farina C
Pharmacological Profile of MP-101, a Novel Non-racemic Mixture of R- and S-dimiracetam with Increased Potency in Rat Models of Cognition, Depression and Neuropathic Pain
Bonifacino T, Micheli L, Torazza C, Ghelardini C, Farina C, Bonanno G
A rat model of FOLFOX-induced neuropathy: effects of oral dimiracetam in comparison with duloxetine and pregabalin
Di Cesare Mannelli L, Maresca M, Micheli L, Farina C, Scherz MW, Ghelardini C
A model of neuropathic pain induced by sorafenib in the rat: Effect of dimiracetam
Di Cesare Mannelli L, Maresca M, Farina C, Scherz MW, Ghelardini C
Synthesis and pharmacological activity of a series of dihydro-1H-pyrrolo[1,2-a]imidazole-2,5(3H,6H)-diones, a novel class of potent cognition enhancers
Pinza M, Farina C, Cerri A, Pfeiffer U, Riccaboni MT, Banfi S
FAQ
FAQ
Dimiracetam is a racetam-related research compound originally described as a cognition-supporting agent, but later studied mainly for chronic pain linked to nerve injury, chemotherapy, or joint wear. The evidence so far is mostly from animal studies, which showed lasting pain-relieving effects even at reduced doses, but solid human, clinical-level evidence is still largely lacking.
Telegram
Have a question about Dimiracetam?
Reach out to us on Telegram for a personalized stack. We'll be happy to help.
Personalized consultation
Want a detailed conversation tailored to your data?
Fill out the prep intake form (your goals, training and health data), and the advisor prepares from it to give genuinely personalized guidance.
Fill out the form~5–7 min · prep questionnaire · confidential · GDPR-compliant
Structure & chemistry
The information here is strictly for educational and scientific purposes. It does not replace medical advice or clinical consultation, and it does not encourage illegal substance or pharmaceutical use. Data is sourced. When in doubt, consult your doctor.